More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate

Thrombosis Research

Volumn 135, Issue 3, 2015, Pages 544-547

  Lindahl, Tomas L ^a   Wallstedt, Maria ^a   Gustafsson, Kerstin M ^a   Persson, Egon ^b   Hillarp, Andreas ^c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b NOVO NORDISK A S   (Denmark)

^c HALMSTAD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; DABIGATRAN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; ANALYZER; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; FEMALE; GROWTH RATE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REDUCTION; SURFACE PROPERTY; BLOOD CLOTTING; DRUG EFFECTS; THROMBOCYTE RICH PLASMA;

ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DABIGATRAN; FACTOR VIIA; HEMOSTATICS; HUMANS; PLATELET-RICH PLASMA; RECOMBINANT PROTEINS;

EID: 84925823784     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.12.019     Document Type: Article

References (26)

1. A. Majeed, H.G. Hwang, S.J. Connolly, J.W. Eikelboom, M.D. Ezekowitz, and L. Wallentin Management and outcomes of major bleeding during treatment with dabigatran or warfarin Circulation 128 2013 2325 2332
2. F. Schiele, J. van Ryn, K. Canada, C. Newsome, E. Sepulveda, and J. Park A specific antidote for dabigatran: functional and structural characterization Blood 121 2013 3554 3562
3. A. Majeed, and S. Schulman Bleeding and antidotes in new oral anticoagulants Best Pract Res Clin Haematol 26 2013 191 202
4. T. Steiner, M. Bohm, M. Dichgans, H.C. Diener, C. Ell, and M. Endres Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban Clin Res Cardiol 102 2013 399 412
5. S. Kaatz, P.A. Kouides, D.A. Garcia, A.C. Spyropolous, M. Crowther, and J.D. Douketis Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Am J Hematol 87 Suppl. 1 2012 S141 S145
6. G. Pernod, P. Albaladejo, A. Godier, C.M. Samama, S. Susen, and Y. Gruel Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013 Arch Cardiovasc Dis 106 2013 382 393
7. D.M. Siegal, and M.A. Crowther Acute management of bleeding in patients on novel oral anticoagulants Eur Heart J 34 2013 489-498b
8. M.A. Crowther, and T.E. Warkentin Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents J Thromb Haemost 7 Suppl. 1 2009 107 110
9. D. Fries, A. Giurea, M. Gutl, W.M. Halbmayer, S. Kozek-Langenecker, and A. Pachucki Management of dabigatran-induced bleeding: expert statement Wien Klin Wochenschr 125 2013 721 729
10. S. Schulman, and M.A. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 2012 3016 3023
11. M. Ranby, S. Ramstrom, P.O. Svensson, and T.L. Lindahl Clotting time by free oscillation rheometry and visual inspection and a viscoelastic description of the clotting phenomenon Scand J Clin Lab Invest 63 2003 397 406
12. N.P. Soshitova, S.S. Karamzin, A.N. Balandina, O.A. Fadeeva, A.V. Kretchetova, and G.M. Galstian Predicting prothrombotic tendencies in sepsis using spatial clot growth dynamics Blood Coagul Fibrinolysis 23 2012 498 507
13. N.M. Dashkevich, M.V. Ovanesov, A.N. Balandina, S.S. Karamzin, P.I. Shestakov, and N.P. Soshitova Thrombin activity propagates in space during blood coagulation as an excitation wave Biophys J 103 2012 2233 2240
14. E. Lipets, O. Vlasova, E. Urnova, O. Margolin, A. Soloveva, and O. Ostapushchenko Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients PLoS One 9 2014 e87692
15. T.L. Khoo, C. Weatherburn, G. Kershaw, C.J. Reddel, J. Curnow, and S. Dunkley The use of FEIBA(R) in the correction of coagulation abnormalities induced by dabigatran Int J Lab Hematol 35 2013 222 224
16. R. Herrmann, J. Thom, A. Wood, M. Phillips, S. Muhammad, and R. Baker Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban Thromb Haemost 111 2014 989 995
17. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
18. P.K. Davis, H. Musunuru, M. Walsh, R. Mitra, V. Ploplis, and F.J. Castellino The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: mechanistic implications for clinical medicine Thromb Haemost 108 2012 586 588
19. I. Pragst, S.H. Zeitler, B. Doerr, F.J. Kaspereit, E. Herzog, and G. Dickneite Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model J Thromb Haemost 10 2012 1841 1848
20. W. Zhou, S. Schwarting, S. Illanes, A. Liesz, M. Middelhoff, and M. Zorn Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran Stroke 42 2011 3594 3599
21. J. van Ryn, J. Schurer, M. Kink-Eiband, and A. Clemens Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation Anesthesiology 120 2014 1429 1440
22. S. Mastrobuoni, J.A. Robblee, and M. Boodhwani Spontaneous ascending aortic intramural haematoma in a patient on dabigatran Interact Cardiovasc Thorac Surg 15 2012 299 300
23. A. Lillo-Le Louet, M. Wolf, L. Soufir, A. Galbois, A.S. Dumenil, and G. Offenstadt Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation Thromb Haemost 108 2012 583 585
24. L.M. Harinstein, J.W. Morgan, and N. Russo Treatment of dabigatran-associated bleeding: case report and review of the literature J Pharm Pract 26 2013 264 269
25. W.E. Dager, R.C. Gosselin, and A.J. Roberts Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity Crit Care Med 41 2013 e42 e46
26. J.L. Aron, R. Gosselin, S. Moll, C.F. Arkin, and S. Mantha Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage J Thromb Thrombolysis 37 2014 76 79